News
-
-
-
COMMUNIQUÉ DE PRESSE
Focus Universal Announces SEC Financial Reporting Software Achieves Thousand Times Faster Than Traditional Manual Approach and Launches Nationwide Non-Deal Roadshow
Focus Universal Inc. (NASDAQ:FCUV) announces revolutionary SEC financial reporting software, generating reports thousands of times faster than traditional methods, enhancing efficiency and accuracy in financial reporting -
-
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration hebdomadaire des transactions sur actions propres du 5 au 9 août 2024.
Déclaration hebdomadaire des transactions sur actions propres de Guillemot Corporation S.A. du 5 au 9 août 2024. Transactions réalisées dans le cadre du programme de rachat via un prestataire indépendant -
COMMUNIQUÉ DE PRESSE
Atlas Salt Announces De-risked Development Schedule for Great Atlantic Salt Project
Atlas Salt Inc. announces de-risked development schedule for Great Atlantic Salt Project with 3rd party verification by Tamkali Limited. Project's duration reduced to 59 months, enhancing details, and incorporating PERT analysis and Oracle Primavera Cloud Software -
COMMUNIQUÉ DE PRESSE
Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration
Monogram Technologies Inc. announces clinical trial collaboration with Shalby Limited for mBÈs TKA System, following 510(k) submission and FDA approval. Shalby recognized as global leader in orthopedic surgeries -
COMMUNIQUÉ DE PRESSE
Grand Island Express Achieves Record-Breaking Efficiency and Revenue Gains With Optimal Dynamics’ Software
Optimal Dynamics' Artificial Decision Intelligence drives significant revenue, load count, and operational efficiency for Grand Island Express trucking company, leading to record-breaking results and high adoption rate -
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
MIRA Pharmaceuticals unveils new preclinical data on innovative drug candidate Ketamir-2's metabolite Nor-Ketamir-2, showcasing enhanced bioavailability and formulation for advanced at-home neurological treatments -
